Senhwa's CX-4945 targets CK2 kinase with dual tumor and immune modulatory mechanisms; CellType's AI platform aims to expand indications and improve clinical success via multi-omics analysis and translational validation.
Generate's $400M IPO signals strong investor confidence, driven by AI-designed pipelines including GB-0895, an AI-optimized TSLP inhibitor with potential to disrupt asthma treatment.
hysiology remains foundational for translating AI and sensor data into clinically relevant therapies, aiding in anticipating off-target effects and enhancing regulatory acceptance.
13 min
About Pharma Digest
From the publisher's feed
A fast paced, AI-generated podcast on pharma and biotech news.